BlackRock’s Supernus Pharmaceuticals SUPN Stock Holding History

BlackRock’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455M	Buy	8,797,254 +61,386	+0.7%	+$3.13M	0.01%	1186
2025 Q4	$434M	Buy	8,735,868 +37,458	+0.4%	+$1.82M	0.01%	1216
2025 Q3	$416M	Sell	8,698,410 -669,484	-7%	-$27M	0.01%	1211
2025 Q2	$295M	Sell	9,367,894 -316,658	-3%	-$10.1M	0.01%	1378
2025 Q1	$317M	Sell	9,684,552 -313,384	-3%	-$11.1M	0.01%	1311
2024 Q4	$362M	Sell	9,997,936 -68,996	-0.7%	-$2.43M	0.01%	1299
2024 Q3	$314M	Sell	10,066,932 -325,704	-3%	-$10.2M	0.01%	1387
2024 Q2	$278M	Buy	10,392,636 +30,280	+0.3%	+$878K	0.01%	1400
2024 Q1	$353M	Sell	10,362,356 -20,414	-0.2%	-$608K	0.01%	1265
2023 Q4	$300M	Buy	10,382,770 +202,865	+2%	+$5.38M	0.01%	1370
2023 Q3	$281M	Buy	10,179,905 +219,482	+2%	+$6.68M	0.01%	1316
2023 Q2	$299M	Buy	9,960,423 +461,053	+5%	+$16.1M	0.01%	1300
2023 Q1	$344M	Sell	9,499,370 -105,522	-1%	-$4.06M	0.01%	1171
2022 Q4	$343M	Buy	9,604,892 +388,318	+4%	+$13.5M	0.01%	1152
2022 Q3	$312M	Buy	9,216,574 +420,429	+5%	+$13.7M	0.01%	1146
2022 Q2	$254M	Sell	8,796,145 -93,430	-1%	-$2.68M	0.01%	1350
2022 Q1	$287M	Buy	8,889,575 +438,553	+5%	+$13.4M	0.01%	1391
2021 Q4	$246M	Sell	8,451,022 -407,715	-5%	-$12.4M	0.01%	1579
2021 Q3	$236M	Sell	8,858,737 -13,315	-0.2%	-$357K	0.01%	1581
2021 Q2	$273M	Sell	8,872,052 -122,174	-1%	-$3.75M	0.01%	1541
2021 Q1	$235M	Buy	8,994,226 +81,425	+0.9%	+$2.28M	0.01%	1617
2020 Q4	$224M	Sell	8,912,801 -166,521	-2%	-$3.58M	0.01%	1527
2020 Q3	$189M	Buy	9,079,322 +175,022	+2%	+$3.97M	0.01%	1427
2020 Q2	$211M	Buy	8,904,300 +350,045	+4%	+$7.73M	0.01%	1324
2020 Q1	$154M	Sell	8,554,255 -180,577	-2%	-$3.79M	0.01%	1351
2019 Q4	$207M	Buy	8,734,832 +444,705	+5%	+$10.8M	0.01%	1457
2019 Q3	$228M	Buy	8,290,127 +100,550	+1%	+$2.98M	0.01%	1319
2019 Q2	$271M	Buy	8,189,577 +134,547	+2%	+$4.61M	0.01%	1203
2019 Q1	$282M	Sell	8,055,030 -20,629	-0.3%	-$768K	0.01%	1158
2018 Q4	$268M	Buy	8,075,659 +72,658	+0.9%	+$3.12M	0.01%	1086
2018 Q3	$403M	Buy	8,003,001 +312,332	+4%	+$15.4M	0.02%	916
2018 Q2	$460M	Buy	7,690,669 +618,722	+9%	+$32.1M	0.02%	791
2018 Q1	$324M	Buy	7,071,947 +169,717	+2%	+$7.08M	0.02%	1013
2017 Q4	$275M	Buy	6,902,230 +120,394	+2%	+$4.76M	0.01%	1129
2017 Q3	$271M	Buy	6,781,836 +54,195	+0.8%	+$2.35M	0.01%	1112
2017 Q2	$290M	Buy	6,727,641 +31,331	+0.5%	+$1.12M	0.02%	1017
2017 Q1	$210M	Buy	6,696,310 +6,692,025	+156,173%	+$179M	0.01%	1249
2016 Q4	$109K	Sell	4,285 -403	-9%	-$9.01K	﹤0.01%	2491
2016 Q3	$116K	Sell	4,688 -54	-1%	-$1.22K	﹤0.01%	2505
2016 Q2	$97K	Buy	4,742 +2,134	+82%	+$37.9K	﹤0.01%	2552
2016 Q1	$39K	Buy	2,608 +1,593	+157%	+$20.8K	﹤0.01%	2500
2015 Q4	$14K	Buy	1,015 +358	+54%	+$5.54K	﹤0.01%	2737
2015 Q3	$9K	Hold	657	–	–	﹤0.01%	2791
2015 Q2	$11K	Sell	657 -110	-14%	-$1.57K	﹤0.01%	2734
2015 Q1	$9K	Hold	767	–	–	﹤0.01%	2797
2014 Q4	$6K	Hold	767	–	–	﹤0.01%	3009
2014 Q3	$7K	Hold	767	–	–	﹤0.01%	2952
2014 Q2	$8K	Buy	+767	New	+$6.83K	﹤0.01%	2940

Other funds holding SUPN

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock's SUPN Position: Q1 2026 in Review

BlackRock increased its Supernus Pharmaceuticals (SUPN) stake by 0.7% in Q1 2026, buying an estimated $3.13M and bringing the position to 8,797,254 shares worth $455M. The position accounts for 0.01% of the portfolio, ranked #1186.

BlackRock first reported a position in SUPN in Q2 2014 and has held it in 48 quarters since. The position peaked at $460M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

BlackRock held 8,797,254 shares of Supernus Pharmaceuticals worth $455M as of Q1 2026.
BlackRock bought 61,386 Supernus Pharmaceuticals shares in Q1 2026, an estimated $3.13M.
Supernus Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q1 2026, its #1186 holding.
BlackRock first reported a position in Supernus Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
BlackRock's Supernus Pharmaceuticals position peaked at $460M in Q2 2018.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.